In England and Wales, prostate cancer is currently the second commonest cause of death from cancer in men. Mortality rates from prostate cancer continue to rise and this year approximately 9000 men are expected to die of the disease. In view of this trend, attention has focused on the early detection of the tumour and on radical treatment (the rate of radical prostatectomy has risen fourfoldl). Controversy surrounds the management of localized prostate cancer. Does early diagnosis and intervention lead to improved survival? Can the morbidity and mortality associated with early intervention be justified?
The cost-benefit ratio of screening for prostate cancer in symptom-free individuals is beyond the scope of this review. Instead we address arguments for and against early intervention. The controversy arises because no data are available from randomized prospective trials comparing expectant therapy with radical prostatectomy. Instead we have to rely on information gained from non-randomized retrospective studies.
LOCALIZED PROSTATE CANCER AND SURVIVAL
Once localized prostate cancer is diagnosed, management options include 'watchful waiting', radical prostatectomy and radical radiotherapy.
Watchful waiting
Much of the controversy centres on articles from Sweden. In one series, 223 men were managed expectantly. A 10- year cancer-specific survival of 87% was reported2. Despite these favourable results, it cannot escape notice that Sweden has the fourth highest death rate from prostate cancer in the world. Pooled analysis of 828 patients in six non-randomized studies of 'watchful waiting' showed a 10year cancer-specific survival of 87% for selected patients3. Observations from this study as well as data from Connecticut4 suggest that men with well or moderately differentiated cancers, who have less than 10 years' expected survival, do not show a survival deficit from expectant therapy. Conversely, the latter study emphasized that men with poorly differentiated disease and at least 10 years' expected survival will eventually succumb to prostate cancer. Another study has also demonstrated that more than half the patients who had no metastasis at diagnosis and survived more than 10 years eventually died of prostate cancer5. Clearly, studies comparing early intervention with 'watchful waiting' are of little value if only 10-year cancerspecific survival are examined.
A potential drawback of 'watchful waiting' studies conducted in the 1 980s is that they may not be equivalent to current radical prostatectomy series. In these 'watchful waiting' series, a high proportion of prostate cancers were detected at the time of transurethral resection of the prostate (TURP) [Ti a or Tlb] (Figure 1 ). With the advent of serum prostate specific antigen (PSA), many radical prostatectomies in the 1990s are performed on younger patients with PSA-detected prostate cancers. Currently, we do not know whether PSA-detected prostate cancer (Tlc) has a different biological activity from that of TURPdetected cancer (Tla or Tlb). Prospective assessment of the pathological features of Tlc tumours suggests that most of these tumours are larger than those detected in necropsy studies and may therefore be clinically significant6.
Radical prostatectomy
The aim of radical prostatectomy is cure by surgical extirpation. Prediction of capsular penetration and discrimination between locally confined and more advanced disease remains difficult. Moreover, the predictive value of existing techniques has not been evaluated prospectively. Of pathological grade and stage, preoperative serum PSA and clinical stage, tumour grade by the Gleason scoring system is the best indicator of survival in both univariate and multivariate analyses7. Tumour volume could not be identified as an independent predictor of progression in a multivariate analysis8. After radical prostatectomy, serum PSA is a sensitive indicator of disease recurrence, becoming detectable 3 to 6 years before clinical recurrence9. Any detectable serum PSA postoperatively signifies disease recurrence. Highly favourable results of radical prostatectomy in men with clinically localized prostate cancer have been published, mainly from university centres. In a Ti: Non-palpable prostate carcinoma Ti a < 5% of TURP chips Ti b > 5% of TURP chips Tic PSA-detected prostate carcinoma TURP=Transurethral resection of the prostate retrospective, non-randomized multi-institutional pooled analysis of 2758 men with stage Ti and T2 cancer, 10 year cancer-specific survivals following surgery were 94% for well-differentiated tumours (Gleason score 2-4), 80% for moderately differentiated tumours (Gleason score 5-7) and 77% for poorly differentiated tumours (Gleason score 8-10)10. In a single institution analysis of 1143 consecutive patients with <T2c prostate cancer, the 10 and 15 year cancer-specific survival rates were 90% and 83%, respectively10.
True radical resection of the prostate gland is difficult because of its intimate relationship with surrounding vulnerable structures particularly posterolaterally in the area of the neurovascular bundle and posteriorly in front of the rectum. A positive surgical margin is defined as the presence of tumour cells at the inked margin of resection. Even in centres of excellence, positive margin rates up to 33%11-13 have been reported. Positive margins appear to have predictive value when the tumour is well or moderately differentiated and has spread beyond the prostate14. Some workers have tried neoadjuvant chemotherapy to downstage the tumour. In randomized trials, neoadjuvant chemotherapy has reduced the incidence of positive margins15'16 but, unfortunately, PSA-defined disease-free survivals have not changed. Positive margins, if found laterally in pathologically confined prostate cancer, may be artefactual14, whereas urethral and bladder neck positive margins may have more clinical significance.
Radical radiotherapy
In the absence of randomized trials, a comparison between surgical treatment and radiotherapy is impossible. Nonrandomized radiotherapy series are more likely to recruit older patients with higher tumour stages. Furthermore, staging is usually performed by various imaging techniques, whereas patients with positive nodes tend to be excluded from surgical series. Unlike radical prostatectomy, radical T2: Palpable but organ-confined prostate carcinoma T2a < half of one lobe T2b > half of one lobe T2c Both lobes system (1992 version) for the T (tumour) category radiotherapy does not totally eliminate the prostate gland. Consequently, biochemical failure following radiotherapy is more difficult to define.
Results on the efficacy of radical radiotherapy are not easily compared17-19. In a 10-year study of 682 patients treated with external beam radiotherapy, 60 had early-stage prostate cancer and their 10-year recurrence-free survival assessed clinically was 77%. A prospective series of 207 consecutive patients with prostate cancer (TI-T4) treated with radiotherapy were followed up for a mean of 36 months with systematic transrectal ultrasound biopsies and measurements of serum PSA levels18. Recurrence-free survival during this time was 67%. Many urologists, noting the failure of radiotherapy to suppress serum PSA to undetectable levels for long intervals, have told patients that radiotherapy will not cure their cancer. A recent assessmYent suggests that this may be an unfair judgment20. In this study, 145 patients with localized prostate cancer received radiotherapy after a negative staging pelvic lymphadenectomy to correct for adverse case selection. The results were impressive with cancer-specific survivals at 10 and 15 years of 84% and 80%, respectively. When a PSA of 1.5 ng/mL was used to define recurrent disease, the disease-free survivals at 10 and 15 years were 42% and 10%, respectively. Clearly, radical radiotherapy achieves good local control of the primary tumour in patients with localized prostate cancer, enabling most of these men to live at least a further 15 years, even though they may not have been cured.
COMPLICATIONS OF EARLY INTERVENTION
Any treatment used for localized prostate cancer should have low morbidity and almost zero mortality. The incidence of incontinence and impotence depends on how they are defined. Moreover the method of collection of data influences results because the treating physicians are more likely than the patient to have a positive view of treatment2'.
Radical prostatectomy
In their review this year, Dillioglugil et al. 22 confirmed the low perioperative mortality rate (0.4%) associated with radical prostatectomy. Assessment of medical status of the two men who died, by the American Society of Anesthesiologists (ASA) physical status classification, revealed that both patients belonged to class III. These results suggest that high-risk patients should be dissuaded from having radical prostatectomy. In a prospective study of 188 consecutive radical prostatectomies, the perioperative mortality rate was 1. 5%23. Other than intraoperative haemorrhage, the immediate complications of surgery relate to the obturator nerve, the ureter and the rectumdamaged in less than 1% of patients if the retropubic approach is used.
The most important long-term goals of radical prostatectomy, in order of importance, are cancer control, recovery of urinary control and preservation of sexual function. Published incontinence rates 12 months postsurgery show wide variations (Table 1) . Important factors are patient age and whether the surgery was performed at specialized centres. Stress incontinence related to exertion is the most common form of incontinence. University centres report incontinence rates of 5-8% at 12 monthse10 23-26. In Walsh's series24, the incontinence was sufficient to require placement of an artificial sphincter in two men (0.3%). Weight of the prostate, previous transurethral resection of the prostate, pathological stage and preservation of neurovascular bundles had no clear influence on urinary control. Results in community practice are often less good. In a retrospective survey of Medicare patients who had radical prostatectomy, 63% of patients complained of some degree of incontinence (31 % needing a permanent appliance) and 43% complained of stress incontinence27. In this series, 80% of patients who completed the questionnaire were older than 70 years compared with 4% in Walsh's series24. In this small group, 14% had incontinence. These two studies clearly show that age is an important predisposing factor for incontinence; patients above 70 years have double the incontinence rates of those under that age.
Three major factors which influence the recovery of sexual function are patient age, pathological stage and surgical technique28. The last refers to preservation of neurovascular bundles, the so-called 'nerve-sparing' prostatectomy. However, the 'nerve sparing' approach can only be offered in carefully selected patients.
In published series, the potency rates after radical prostatectomy have varied widely (Table 1) . This variability may arise because of different definitions. It takes 1-2 years for sexual function to recover, so studies evaluating impotence rates within one year of follow-up may be overestimating the problem. Patients who are impotent before surgery are not always excluded from the final results. Of 503 patients who were potent preoperatively, Quinlan et al. reported that 32% were impotent after 18 months' follow-up28. In men under 50 years old, potency was similar in patients who had both neurovascular bundles preserved (90%) and patients who had one neurovascular bundle widely excised (91%). In men over 50 years of age, sexual function was significantly better if both neurovascular bundles were preserved than in those in whom one neurovascular bundle was excised. Clearly, evaluation of sexual performance in patients less than 50 years who undergo surgery, is a good way of assessing surgical technique.
Radical radiotherapy
Complications of external beam radiotherapy seem related to total dosage, treated volume, distribution of dosage, fractionation schema and expertise. The treatment-related complications consist of intestinal and bladder problems, impotence and oedema of the extremities. The overall incidence of significant urinary and/or digestive complica-tions29 ranges from 3% (severe) to 7% (moderate). Erectile dysfunction affects 15-56% of patients, the worst figures being found in studies in which the patient's own opinion is sought in self-assessment questionnaires30. However, there have been no prospective studies of the sexual consequences of radiotherapy. CONCLUSION Proponents of early intervention and advocates of expectant management claim similar mortality outcomes and debate the morbidity of each approach. Unfortunately, both groups of investigators have selected patients who are likely to perform well irrespective of the intervention. The Prostate Intervention Versus Observation Trial (PIVOT) in the USA and a Scandinavian trial are randomized prospective studies comparing radical prostatectomy with expectant treatment. However, interpretable results will not be available until approximately 2010. Meanwhile, the difficulty in managing prostate cancer can be handled pragmatically through decision-analysis modelling. Medically fit patients aged <70 with organ confined but high-grade prostate cancer may live longer if they are treated with radical prostatectomy. Morbidity is low if the procedure is performed in those < 70 years, ASA classes I or II and in centres of excellence.
